Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli

Glycobiology

Volumn 26, Issue 1, 2015, Pages 51-62

  Ravenscroft, Neil ^a   Haeuptle, Micha A ^b   Kowarik, Michael ^b   Fernandez, Fabiana S ^b   Carranza, Paula ^b   Brunner, Andreas ^b   Steffen, Michael ^b   Wetter, Michael ^b   Keller, Sacha ^b   Ruch, Corina ^b   Wacker, Michael ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GlycoVaxyn AG   (Switzerland)

Author keywords

biosynthetic glycoconjugate vaccine; E. coli glycosylation; O polysaccharide; Shigella dysenteriae type 1; vaccine development

Indexed keywords

ASPARAGINE; BACTERIAL POLYSACCHARIDE; EXOTOXIN; GLYCOCONJUGATE; MONOSACCHARIDE; OLIGOSACCHARIDE; SHIGELLA VACCINE; BACTERIAL PROTEIN; ENDOTOXIN; GLYCOPROTEIN; GLYCOSYLTRANSFERASE; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; VACCINE;

ANTIGEN EXPRESSION; ARTICLE; BACTERIAL CELL; BIOENGINEERING; BIOSYNTHESIS; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; ESCHERICHIA COLI; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SHIGELLA DYSENTERIAE; SHIGELLA DYSENTERIAE TYPE 1; SHIGELLOSIS; VACCINE PRODUCTION; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; PROTEIN PROCESSING;

BACTERIAL PROTEINS; ENDOTOXINS; ESCHERICHIA COLI; GLYCOPROTEINS; GLYCOSYLATION; GLYCOSYLTRANSFERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; PSEUDOMONAS AERUGINOSA; SHIGELLA DYSENTERIAE; VACCINES, CONJUGATE;

EID: 84960413009     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwv077     Document Type: Article

References (46)

1. Apicella MA. 2008. Isolation and characterization of lipopolysaccharides. Methods Mol Biol (Clifton, NJ). 431:3-13.
2. Brooks JT, Ochieng JB, Kumar L, Okoth G, Shapiro RL, Wells JG, Bird M, Bopp C, Chege W, Beatty ME, et al. 2006. Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya, 1997-2003. Clin Infect Dis. 43:393-401.
3. Cohen D, Sela T, Slepon R, Yavzori M, Ambar R, Orr N, Robin G, Shpielberg O, Eldad A, GreenM. 2001. Prospective cohort studies of shigellosis during military field training. Eur J Clin Microbiol Infect Dis. 20:123-126.
4. Coxon B, Sari N, BattaG, PozsgayV. 2000.NMRspectroscopy,molecular dynamics, and conformation of a synthetic octasaccharide fragment of the O-specific polysaccharide of Shigella dysenteriae type 1. Carbohydr Res. 324:53-65.
5. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA. 97:6640-6645.
6. Dmitriev BA, Knirel YA, Kochetkov NK. 1976. Somatic antigens of shigella. Structural investigation on the O-specific polysaccharide chain of Shigella dysenteriae type 1 lipopolysaccharide. Eur J Biochem. 66:559-566.
7. Dykxhoorn DM, St Pierre R, Linn T. 1996. A set of compatible tac promoter expression vectors. Gene. 177:133-136.
8. Feldman MF,Wacker M, Hernandez M, Hitchen PG, Marolda CL, KowarikM, Morris HR, Dell A, Valvano MA, Aebi M. 2005. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA. 102:3016-3021.
9. Fernandez MI, Sansonetti PJ. 2003. Shigella interaction with intestinal epithelial cells determines the innate immune response in shigellosis. Int J Med Microbiol. 293:55-67.
10. Friedman AM, Long SR, Brown SE, Buikema WJ, Ausubel FM. 1982. Construction of a broad host range cosmid cloning vector and its use in the genetic analysis of Rhizobium mutants. Gene. 18:289-296.
11. Hatz Christoph FR, Bally B, Rohrer S, Steffen R, Kramme S, Siegrist C, Wacker M, Alaimo C, Fonck VG. 2015. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study. Vaccine. 33:4594-4601.
12. Ihssen J, Kowarik M, Dilettoso S, Tanner C,Wacker M, Thony-Meyer L. 2010. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact. 9:61.
13. Jones C, Lemercinier X. 2002. Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture. J Pharm Biomed Anal. 30:1233-1247.
14. Kämpf MM, Braun M, Sirena D, Ihssen J, Thöny-Meyer L, RenQ. 2015. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: Identification of stimulating factors for in vivo glycosylation. Microb Cell Fact. 14:651.
15. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, et al. 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS). A prospective, case-control study. Lancet. 382:209-222.
16. Leyva A, Quintana A, Sanchez M, Rodriguez EN, Cremata J, Sanchez JC. 2008. Rapid and sensitive anthrone-sulfuric acid assay in microplate format to quantify carbohydrate in biopharmaceutical products. method development and validation. Biologicals. 36:134-141.
17. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, et al. 2012. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet. 379:2151-2161.
18. Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, Marohn ME, Antonio M, Hossain A, Mandomando I, Ochieng JB, et al. 2014. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin Infect Dis. 59:933-941.
19. Lundborg M, Fontana C, Widmalm G. 2011. Automatic structure determination of regular polysaccharides based solely on NMR spectroscopy. Biomacromolecules. 12:3851-3855.
20. Lv L, Yang X, Zhao Y, Ruan Y, Yang Y, Wang Z. 2009. Separation and quantification of component monosaccharides of the tea polysaccharides from Gynostemma pentaphyllum by HPLC with indirect UV detection. Food Chem. 112:742-746.
21. Niyogi SK. 2005. Shigellosis. J Microbiol (Seoul, Korea). 43:133-143.
22. No authors listed. 2000. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO Tech Rep Ser. 897:27-56.
23. No authors listed. 2004. Recommendations for the production and control of meningococcal group C conjugate vaccines. WHO Tech Rep Ser. 924:102-128.
24. No authors listed. 2005. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser. 927:64-98.
25. No authors listed. 2006. Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccines. WHO Tech Rep Ser. 962:117-171.
26. Passwell JH, Ashkenazi S, Harlev E, MironD, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, et al. 2003. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one-to four-year-old children. Pediatr Infect Dis J. 22:701-706.
27. Passwell JH, Ashkenzi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, et al. 2009. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine. 28:2231-2235.
28. Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, et al. 2001. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun. 69:1351-1357.
29. Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Belot F, Cohen D, Sansonetti PJ, Mulard LA. 2009. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J Immunol. 182:2241-2247.
30. Pozsgay V, Chu C, Pannell L, Wolfe J, Robbins JB, Schneerson R. 1999. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci USA. 96:5194-5197.
31. Pozsgay V, Kubler-Kielb J, Schneerson R, Robbins JB. 2007. Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proc Natl Acad Sci USA. 104:14478-14482.
32. Putnam SD, Riddle MS, Wierzba TF, Pittner BT, Elyazeed RA, El-Gendy A, Rao MR, Clemens JD, Frenck RW. 2004. Antimicrobial susceptibility trends among Escherichia coli and Shigella spp. isolated from rural Egyptian paediatric populations with diarrhoea between 1995 and 2000. Clin Microbiol Infect. 10:804-810.
33. Robbins JB, Chu C, Schneerson R. 1992. Hypothesis for vaccine development: Protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis. 15:346-361.
34. Samandari T, Kotloff KL, Losonsky GA, Picking WD, Sansonetti PJ, Levine MM, Sztein MB. 2000. Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol. 164:2221-2232.
35. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. 1985. Measurement of protein using bicinchoninic acid. Anal Biochem. 150:76-85.
36. Sturm S, Timmis KN. 1986. Cloning of the rfb gene region of Shigella dysenteriae 1 and construction of an rfb-rfp gene cassette for the development of lipopolysaccharide-based live anti-dysentery vaccines. Microb Pathogenesis. 1:289-297.
37. Szu SC. 2013. Development of Vi conjugate-A new generation of typhoid vaccine. Expert Rev Vaccines. 12:1273-1286.
38. Vella M, Pace D. 2015. Glycoconjugate vaccines: An update. Expert Opin Biol Ther. 15:529-546.
39. von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh DG, Chaicumpa W, Agtini MD, Hossain A, et al. 2006. A multicentre study of Shigella diarrhoea in six Asian countries: Disease burden, clinical manifestations, and microbiology. PLoS Med. 3:e353.
40. Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, Panico M, Morris HR, Dell A, Wren BW, et al. 2002. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science. 298:1790-1793.
41. Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, Shields K, Park S, Alaimo C, Kelley KA, et al. 2014. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis. 209:1551-1561.
42. Walker RI. 2005. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine. 23:3369-3385.
43. Walker RI. 2015. An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children. Vaccine. 33:954-965.
44. Wang XY, Du L, von Seidlein L, Xu ZY, Zhang YL, Hao ZY, Han OP,Ma JC, Lee HJ, Ali M, et al. 2005. Occurrence of shigellosis in the young and elderly in rural China. results of a 12-month population-based surveillance study. Am J Trop Med Hyg. 73:416-422.
45. Wetter M, Kowarik M, Steffen M, Carranza P, Corradin G, Wacker M. 2013. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component. Glycoconj J. 30:511-522.
46. Zafar A, Hasan R, Nizami SQ, von Seidlein L, Soofi S, Ahsan T, Chandio S, Habib A, Bhutto N, Siddiqui FJ, et al. 2009. Frequency of isolation of various subtypes and antimicrobial resistance of Shigella from urban slums of Karachi, Pakistan. Int J Infect Dis. 13:668-672.